GSK1292263

Cat. No.: HY-12066
CAS No.: 1032823-75-8
Molecular Formula: C₂₃H₂₈N₄O₄S
Molecular Weight: 456.56
Target: GPR119
Pathway: GPCR/G Protein; Neuronal Signaling
Storage: Powder
-20°C 3 years
4°C 2 years
In solvent
-80°C 6 months
-20°C 1 month

**SOLVENT & SOLUBILITY**

**In Vitro**

DMSO: ≥ 20 mg/mL (43.81 mM)
* "≥" means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>2.1903 mL</td>
<td>10.9515 mL</td>
<td>21.9029 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.4381 mL</td>
<td>2.1903 mL</td>
<td>4.3806 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.2190 mL</td>
<td>1.0951 mL</td>
<td>2.1903 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: **10% DMSO >> 90% corn oil**

Solubility: ≥ 2 mg/mL (4.38 mM); Clear solution

**BIOLOGICAL ACTIVITY**

GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. IC₅₀ value: Target: GPR119 in vitro: GSK-1292263 is selected from 1538 compounds by using Hypo1, the Fit-Value and Estimate of GSK-1292263 that is aligned in Hypo1 are 8.8 and 7.7 (nM), respectively [1]. in vivo: GSK-1292263 administrated at a single dose of 3-30 mg/kg in the absence of nutrients correlates with increased levels of circulating gastrointestinal peptides, including glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), peptide YY (PYY) and glucagon in male Sprague-Dawley rats, the increase is enhanced following administration of glucose in the oral glucose tolerance test (OGTT). GSK-129226 significant increases in the peak insulin response and insulin AUC(0-15 min) of 30-60% compared with values in the vehicle control cohort in the intravenous glucose tolerance test in rats, this insulin upregulation correlated with a significant increase in the glucose disposal rate. GSK-1292263 is associated with a statistically significant increase in insulin immunoreactivity in pancreatic sections in a 6-week study performed...
in Zucker diabetic fatty rats, compared with insulin immunoreactivity in samples obtained from rats receiving vehicle control. GSK-1292263 administrated at dose of 10 or 30 mg/kg or vehicle control at 2 hours prior to insulin infusion in hyperinsulinemic-euglycemic clamps stimulates glucagon secretion without increasing blood glucose levels Sprague-Dawley rats [2].

CUSTOMER VALIDATION

- College of Pharmacy. Seoul National University. 2015 Aug.

See more customer validations on www.MedChemExpress.com

REFERENCES

